Abstract. Chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing 1 (CMTM1) consists of at least 23 alternatively spliced isoforms designated CMTM1_ v1-v23. In the present study, we detected CMTM1_v17 expression in multiple human normal and tumor tissues and found that CMTM1_v17 was highly expressed in testis and many tumor tissues including breast tumor. The overexpression of CMTM1_v17 in the breast cancer cell line MDA-MB-231 promoted cell proliferation and resistance to tumor necrosis factor-α (TNF-α)-induced apoptosis. Moreover, siRNA-mediated silencing of CMTM1_v17 sensitized MDA-MB-231 cells to TNF-α-induced apoptosis. We propose that CMTM1_v17 may be a novel potential target for therapy in breast cancer patients. The present study provides insight into a novel mechanism by which CMTM1_v17 enhances cellular proliferation and abrogates TNF-α-induced apoptosis. These findings also have implications for clinical practice as they highlight the potential for therapeutic targeting of CMTM1_v17 for the treatment of breast and other cancers in which CMTM1_v17 impacts cellular proliferation and survival.
Introduction
Chemokine-like factor (CKLF) was first isolated from PHA-stimulated U937 cells (1) . Since then, eight novel genes of the CKLF family have been identified through BLAST searches in combination with expressed sequence tag assembly and have been experimentally validated. They have been designated as chemokine-like factor superfamily (CKLFSF) members and have been approved by the HUGO Gene Nomenclature Committee (2) . In 2005, CKLFSF1-8 were renamed CKLF-like MARVEL transmembrane domain containing [1] [2] [3] [4] [5] [6] [7] [8] . CKLF and CMTM1-8 represent a novel protein family linking the chemokine and TM4SF families that may play multiple roles in a wide range of physiological and pathological processes. CKLF1 has chemotactic effects on a wide spectrum of leukocytes, while CKLF2 stimulates the proliferation and differentiation of C2C12 cells (3) . Rat and mouse cklf have similar RNA splice forms and functions as human CKLF (4, 5) .
Our laboratory cloned and characterized CMTM1, which is highly expressed in testis tissue. The CMTM1 gene consists of seven exons and six introns. Most of the intron-exon boundaries agreed with the GT/AG rule and two alternative transcription start sites, 1A and 1B, were identified. Site 1A predicted a complete open reading frame ORF1. Site 1B, located inside the putative exon 1, predicted a shorter open reading frame ORF2. cDNA sequencing revealed that CMTM1 contains at least 23 alternatively spliced isoforms, which were designated CMTM1_v1-v23 (suggested by the HUGO Gene Nomenclature Committee). The proteins of CMTM1_v1-16 are encoded by ORF1 and ORF2 encodes CMTM1_v17-23.
CMTM1 is most abundant in spermatocytes of human testicular tissues (6) and is highly upregulated and greatly susceptible to the effect of hrIL-30 in PC3 cells (7) . CMTM2 is a secreted protein that may be functionally relevant during spermatogenesis (8) . CMTM8 is a novel negative regulator of epidermal growth factor-induced signaling via facilitation of ligand-induced receptor endocytosis and subsequent desensitization (9) . CMTM3 is highly conserved and highly expressed in both the immune system and the male reproductive system (10) . It was reported that CMTM3-5 (11) (12) (13) and CMTM7 (14) all exhibited inhibitory effects on the growth of tumor cells. However, the functions of another member of the CKLFSF family, CMTM6, are largely undefined.
In the present study, we found that CMTM1_v17 was highly expressed in human testis and many human tumor tissues, and cell lines but was almost undetectable in human normal tissues. CMTM1_v17 had enhanced proliferation and resisted tumor necrosis factor-α (TNF-α)-induced apoptosis. We suggest that CMTM1_v17 may be a novel potential therapeutic target in breast cancer patients and it may also be a novel potential cancer/testis antigen.
Materials and methods
Cell culture and transfection. The human cell lines HEK293T (a gift from T. Matsuda, Japan), HEK293, MDA-MB-231, MCF-7, HepG2, SGC7901, AGS, Caov3, HeLa and H1299 were cultured in Dulbecco's modified Eagle's medium (DMEM; Life Technologies, USA) containing 10% fetal bovine serum (FBS; HyClone, USA), 100 U/ml penicillin, and 100 µg/ml streptomycin at 37˚C in a humidified incubator with 5% CO 2 . The suspension cell lines K562, Raji and U937 were maintained in RPMI-1640 medium supplemented with FBS and antibiotics as above. MDA-MB-231 cells were plated in fresh culture medium prior to initiating experiments. The indicated amount of siRNA plus plasmid or plasmid alone was transfected into MDA-MB-231 cells using Lipofectamine 2000 (Invitrogen, USA) according to the manufacturer's protocol.
cDNA preparation and real-time qPCR. cDNA preparations of normal tissues were purchased from Clontech (Mountain View, CA, USA). Tumor tissues were gifts from Beijing Shijitan Hospital. Three pathologists evaluated all the tissues to establish the presence of tumors. Tumor tissues were homogenated and pellet cells were suspended in TRIzol reagent (Invitrogen) for the isolation of total RNA according to the manufacturer's instructions. cDNA was synthesized from 3 µg of total RNA using the ThermoScript™ RT-PCR System (Invitrogen). We prepared cDNA from multiple cell lines. The resulting cDNA products were used to amplify the fragment of CMTM1_v17 (forward, 5'-ATG TTG AAG ATC CTG AGA CT-3' and reverse, 5'-CAA TGT AAA TAG GTC AGC AA GTG GTG-3') by real-time qPCR using the Power SYBR-Green PCR Master Mix on a AB7500 System (both from Applied Biosystems, USA) as follows: 95˚C for 30 sec, 40 cycles of 95˚C for 15 sec, 60˚C for 1 min. The mRNA levels of CMTM1_v17 were normalized using GAPDH mRNA levels. Tissues that were utilized for RNA or protein extraction were frozen in liquid nitrogen immediately after harvesting. All samples were obtained from patients with their informed consent and the approval of the Ethics Committee.
cDNA cloning and vector construction. The CMTM1_v17 gene was amplified from a cDNA library of the human breast cancer cell line MDA-MB-231 by PCR using the primers: forward, 5'-ATG TTG AAG ATC CTG AGA CT-3' and reverse, 5'-GCA CGT GTC TGT CGA ATC GCT-3'. The purified PCR product was ligated into the pGEM-T Easy vector (Promega, Madison, WI, USA) and the insert was released by EcoRI digestion and ligated into the EcoRI site of pcDNA.3.1/myc-His(-)B (Invitrogen) to construct the plasmid pcDB/CMTM1_v17. The reverse primer (5'-TCGGATCCACGTCTCGTAAAA-3') was fused with a C-terminal GFP tag in pEGFP-N1 (Clontech) vector by BamHI to construct the plasmid CMTM1_v17-EGFP. A C-terminal human CMTM1_v17 cDNA fragment encoding a 31 amino acid hydrophilic region was amplified from the human breast cancer cell line MDA-MB-231 cDNA library using the primers forward, 5'-GAA AAG ATT CCT GGG AGT CG-3' and reverse, 5'-GCA CGT GTC TGT CGA ATC GCT-3'. The PCR product was cloned into pGEX-4T-2 (Pharmacia, USA) for expression in E. coli. All clones were confirmed by sequencing. All plasmids were purified using Qiagen Plasmid kit (Qiagen, Germany) columns.
Confocal microscopy. To determine the subcellular localization of CMTM1_v17, HEK293T cells transfected with control EGFP or CMTM1_v17-EGFP were fixed in 4% paraformaldehyde for 15 min and permeabilized with 0.2% Triton X-100 for 1 h at room temperature. Cells were rinsed with phosphatebuffered saline (PBS) and stained with DAPI for nuclear visualization. Fluorescence was detected by confocal microscopy (Leica TCS SP5; Confocal System, Germany).
Synthesis of CMTM1_v17 small interfering RNAs. Human
CMTM1_v17 double-stranded small interference RNA was synthesized from GeneChem Corporation (Shanghai, China). The sense oligonucleotide, 5' ACC ACU UGC UGA CCU AUU UdTdT and the antisense oligonucleotide, 5' AAA UAG GUC AGC AAG UGG UdTdT were utilized.
Antibody preparation. The GST fusion protein was expressed and purified as described in the GST Gene Fusion System manual (Pharmacia). Polyclonal anti-CMTM1_v17 antiserum was raised in rabbits immunized with the purified GST fusion protein.
Immunoreactive serum was identified by ELISA and western blotting (data not shown). The GST tag of the fusion protein was removed with thrombin and the purified antigen was coupled to a chromatographic matrix (Sepharose 4B; Pharmacia). The column was used to purify highly-specific, polyclonal anti-CMTM1_v17 antibodies from the antiserum.
Western blotting. Lysates were harvested from primary tissues and cell lines. Protein lysates (30-50 µg) were separated by SDS-PAGE and transferred to nitrocellulose membranes. After transferring, the membranes were blocked in 5% non-fat dry milk in TBS-T for 2 h at room temperature followed by incubation overnight at 4˚C with primary antibodies that were specific for CMTM1_v17, phospho-IKK, IKKβ and IκBα (1:1,000; Cell Signaling). Blots were washed with TBS-T and then incubated at room temperature for 1 h with the appropriate IRDye™ 800-conjugated secondary antibodies (LI-COR Biosciences, USA). Immunocomplexes were detected using Odyssey Infrared Imager System (LI-COR Biosciences). Membranes were re-probed with β-actin monoclonal antibody to confirm equal loading.
Tissue microarrays and immunohistochemistry. Three tissue microarray slides (lot nos. CC08-02-004, CC08-11-001 and CC08-11-002) containing tumor, normal and non-cancerous specimens were purchased from Cybrdi (Xi'an, Shaanxi, China). The slides were dewaxed by rinsing with xylene followed by graded ethanol washes and then heated twice in 10 mmol/l sodium citrate (pH 6.0) for 5 min each in a microwave oven for antigen retrieval. Endogenous peroxidase activity was blocked in methanol containing 3% hydrogen peroxide for 10 min at room temperature. After washing with PBS, the slides were incubated at room temperature for 10 min in 10% normal goat serum/1X PBS. Then, the slides were incubated with rabbit polyclonal antibody to human CMTM1_v17 for 1 h at room temperature. A monoclonal anticancer antigen 15-3 (CA15-3) antibody (Zhongshan, Beijing, China) was used as a positive control. After adequate washing, they were subjected to HRP-labeled polymer for 30 min and DAB + substrate -chromogen solution for 5 min (ChemMate™ DAKO EnVision™ System; Dako, USA). All stained sections were counterstained with hematoxylin, then dehydrated and mounted with coverslips.
Cell growth analysis. Cell viability was assessed by trypan blue staining followed by counting of the unstained cells. Relative cell numbers were determined using the MTT colorimetric assay. Transfected cells were plated in 96-well plates at a density of 2,000 cells/well in 100 µl medium. At the indicated time points, MTT solution was added and samples were incubated for 4 h. After that, the absorbance was measured at a wavelength of 570 nm. Each group was assayed in triplicate and each experiment was repeated three times. Dual luciferase assay. Transient transfection of HEK293T cells was performed using VigoFect (Vigorous) according to the manufacturer's instructions. The relative luciferase activity was determined with a Dual-Luciferase Reporter Assay System (Promega) using a Veritas Microplate Luminometer (USA) by measuring firefly luciferase activity normalized by Renilla luciferase activity.
Statistical analysis.
A Chi-square test was used to compare the expression of CMTM1_v17 between normal and tumor tissues. A p-value (two-sided) of 0.05 was considered to indicate a statistically significant result. Statistical analysis was performed using SigmaStat 2.03 software (SPSS, Inc.).
Results
Expression pattern of CMTM1_v17 mRNA. The expression pattern of human CMTM1_v17 mRNA transcripts was determined by real-time qPCR. CMTM1_v17 mRNA was highly expressed in testicular tissue, but was expressed at a low or undetectable level in other tissues (Fig. 1A) . However, expression of CMTM1_v17 mRNA was detected in tumor tissues from breast, kidney, lung, liver and ovarian cancers, but not colon or rectal cancers (Fig. 1B) . We also found that the expression level of CMTM1_v17 mRNA was high in K562 and U937 cells, moderate in MDA-MB-231 and Caov3, and relatively low in other cells lines (Fig. 1C) .
Subcellular localization of CMTM1_v17. To investigate the subcellular localization of the human CMTM1-v17 protein, we examined the localization of the CMTM1_v17-EGFP construct using confocal fluorescence microscopy. In the cells that overexpressed the control EGFP vector, the fluorescence was distributed throughout the transfected cells with no specific subcellular localization while in the cells overexpressing CMTM1_v17-EGFP, moderate fluorescence was detected only in the cytoplasm (Fig. 1D) .
Expression of CMTM1_v17 is more prevalent in breast tumor
than in normal breast tissues. CMTM1_v17 protein was detected in both breast tumor and adjacent non-cancerous mammary tissues by western blotting. In these samples, CMTM1_v17 expression was more prevalent in tumor than in normal breast tissues (Fig. 2) . CMTM1_v17 was detected in 13/20 (65.00%) tumors compared to only 2/17 (11.76%) non-cancerous breast tissues (Table I) (Table IIB) . Table III shows the correlation analysis (McNemar's test, p>0.05) between CMTM1_v17 and CA15-3 in normal/non-cancerous samples (Table IIIA) or in tumor samples (Table IIIB) . The co-staining of CMTM1_v17 and CA15-3 increased the positive rate to 83.81%.
CMTM1_v17 promotes the proliferation of MDA-MB-231 cells.
The breast cancer cell line MDA-MB-231 was transfected with CMTM1_v17 or control vector and then the cells were assayed for proliferation. Results obtained from cell counting and MTT analysis showed that CMTM1_v17 had an obviously positive effect on the growth of MDA-MB-231 cells (Fig. 4) .
CMTM1_v17 increases the resistance of MDA-MB-231 cells to TNF-α-induced apoptosis.
Since CMTM1_v17 promoted proliferation of MDA-MB-231 cells, we considered whether it also played a role in cellular apoptosis. To investigate this possibility, MDA-MB-231 cells were transiently transfected with CMTM1_v17 or control vector and stimulated with TNF-α. The percentage of Annexin V-positive cells (15.95%) in CMTM1_v17 overexpressing cells was much lower than that in cells transfected with the control vector (23.30%) at 24 h (Fig. 5A) . The result was more marked at 48 h (Fig. 5B) .
Similar results were obtained with human MCF-7 cells (data not shown).
Silencing of CMTM1_v17 expression sensitizes MDA-MB-231 cells to TNF-α-induced apoptosis.
We next investigated A, Correlation analysis between CMTM1_v17 and CA15-3 in normal/non-cancerous samples (McNemar's test, p>0.05).
CA15-3 Normal/non-cancerous -----------------------------------------------------samples (n=127)
Negative Positive   CMTM1_v17  Negative  86  18  Positive  13  10 B, Correlation analysis between CMTM1_v17 and CA15-3 in tumor samples (McNemar's test, p>0.05).
CA15-3 -----------------------------------------------------Tumor samples (n=105)
Negative Positive   CMTM1_v17  Negative  17  18  Positive  20  50 whether the silencing of CMTM1_v17 expression sensitized MDA-MB-231 cells to TNF-α-induced apoptosis. CMTM1-v17 expression was silenced using targeted siRNA and non-silencing siRNA as a control. Annexin V/PI staining was used to detect apoptotic cells after exposure to TNF-α.
We found that siRNA-mediated silencing of CMTM1-v17 restored the sensitivity of MDA-MB-231 cells to TNF-α-induced apoptosis (Fig. 5) . These data further demonstrate that CMTM1-v17 promotes cellular resistance to TNF-α-induced apoptosis. CMTM1_v17 may function via activation of the NF-κB signaling pathway. To investigate the mechanisms underlying the enhanced proliferation and resistance to TNF-α-induced apoptosis in cells overexpressing CMTM1_v17, we performed luciferase reporter assays in HEK293T cells for NF-κB activity by transiently transfecting pcDB or CMTM1_v17 with NF-κB-luciferase and control Renilla reporter plasmids. As is shown, CMTM1_v17 significantly increased the transcriptional activity of NF-κB in a time- (Fig. 6A ) and dose- (Fig. 6B ) dependent manner. These data suggest that overexpression of CMTM1_v17 plays a tonic effect on the activation of NF-κB signaling. To provide further experimental evidence, we performed western blot analysis to detect the key members of NF-κB signaling pathway. In cells that overexpressed CMTM1_v17, we detected increased IKK phosphorylation and decreased expression of total IκBα. Total IKKβ and β-actin expression levels served as a loading control (Fig. 6C) . Taken together, the data from luciferase assays and western blot analysis suggest that activation of the NF-κB pathway by CMTM1_v17 was likely mediated via phosphorylation of IKK and decreased levels of total IκBα.
Discussion
In the present study, we found that CMTM1_v17 was specifically highly expressed in human testes, many human tumor tissues and cell lines but was largely undetectable in the other normal tissues tested. This was consistent with our previous study (6) , in which northern blot analysis revealed that CMTM1 was highly expressed in testicular tissue while it was hardly detectable in other normal tissues. The distinctive expression profile of CMTM1_v17 in human tissues, namely its high expression in multiple neoplastic tissues and cell lines and its absence in normal tissues except for the testes, suggests that the CMTM1_v17 may contribute to tumorigenesis by increasing cellular proliferation. In recent years, it has became evident that breast cancer is one of the most common malignancies and a leading cause of mortality among women. The sporadic (non-inherited) breast cancer that constitutes >90% of all breast cancers is a complex and heterogeneous disease at both the clinical and molecular levels. Several genetic aberrations and changes in gene expression have been shown to occur during malignant transformation, development and progression of breast cancers (15) . TNF-α can induce multiple mechanisms to initiate apoptosis in many tumor cell lines and causes tumor necrosis in certain animal models by binding its membrane receptor TNF-R1 (16). Our findings showed that, compared to normal breast tissues, the expression of CMTM1_v17 was higher in breast tumors. Moreover, ectopic expression of CMTM1_v17 in breast cancer cells promoted the proliferation as well as the resistance to TNF-α-induced apoptosis of breast cancer cell MDA-MB-231 while silenced CMTM1_v17 expression sensitized cells to TNF-α-induced apoptosis. We hypothesized that the abnormal expression of CMTM1_v17 in breast cancer might have clinical applications; in particular, it might be a novel marker of diagnosis and a therapeutic target in breast cancer.
It is well known that NF-κB induces a variety of antiapoptotic factors (17) . To provide further mechanism evidence, the dual-luciferase reporter assay and western blot analysis were performed and the results suggested that overexpression of CMTM1_v17 protein induced robust NF-κB activation. Therefore, we demonstrated that CMTM1_v17 could promote the proliferation and lead to partial resistance to TNF-α induced apoptosis likely via activation of the NF-κB signaling pathway.
In summary, we found that CMTM1_v17 was highly expressed in a variety of tumors including breast cancer. Overexpression of CMTM1_v17 in the cell line MDA-MB-231 promoted proliferation and enhanced the resistance to TNF-α-induced apoptosis likely via activation of the NF-κB pathway. Moreover, silencing of CMTM1_v17 restored the sensitivity of the cells to TNF-α-induced apoptosis. These data indicate that CMTM1_v17 is a novel potential therapeutic target in Figure 6 . Overexpression of CMTM1_v17 activates the NF-κB signaling pathway. HEK293T cells were co-transfected with CMTM1_v17 or a control vector, along with NF-κB-luciferase and control Renilla reporter plasmids. (A) At the indicated time points, the cells were harvested to measure NF-κB induction by calculating the luciferase/Renilla ratio. (B) HEK293T cells were co-transfected with CMTM1_v17 or a control vector and NF-κB-luciferase and control Renilla reporter plasmids at the indicated concentrations. After 18 h, the cells were harvested and NF-κB induction was measured. (C) After overexpression of CMTM1_v17 for 12 h, the expression of pIKK, total IKKβ and IκBα was measured by immunoblotting of whole cell lysates. breast cancer and may play an important role in its diagnosis. CMTM1_v17 may also be a new cancer/testis antigen, as it is also highly expressed in human testes while it is almost undetectable in other normal human tissues. Further studies are required to confirm the therapeutic efficacy of targeting CMTM1_v17 in breast cancer.
